XML 24 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended 192 Months Ended
Mar. 31, 2012
Mar. 31, 2011
Mar. 31, 2012
Revenues:      
Research material sales $ 0 $ 0 $ 580
Contract research and development from related parties 0 0 1,128
Research grants and other 0 0 1,061
Total revenues 0 0 2,769
Operating cost and expenses:      
Cost of research material sales 0 0 382
Research and development 3,580 4,440 93,844
General and administration 2,183 2,316 77,507
Depreciation and amortization 2 0 2,365
Loss on facility sublease 0 0 895
Asset impairment loss and other (gain) loss 0 0 2,445
Total operating costs and expenses 5,765 6,756 177,438
Loss from operations (5,765) (6,756) (174,669)
Other income (expense):      
Valuation of reclassified equity instruments 491 0 16,071
Conversion inducement expense 0 0 (18,234)
Derivative valuation gain/(loss) 348 (161) 1,130
Gain on sale of intellectual property and property and equipment 0 0 3,664
Interest expense (5,225) (1,491) (46,789)
Interest income and other 0 0 1,707
Net loss (10,151) (8,408) (217,120)
Issuance of common stock in connection with elimination of Series A and Series A-1 preferred stock preferences 0 0 (12,349)
Warrants issued on Series A and Series A-1 preferred stock dividends 0 0 (4,664)
Accretion of Series A preferred stock mandatory redemption obligation 0 0 (1,872)
Series A preferred stock redemption fee 0 0 (1,700)
Beneficial conversion feature of Series D preferred stock 0 0 (4,274)
Net loss applicable to common stockholders (10,151) (8,408) (261,929)
Net loss per share applicable to common stockholders - basic (in dollars per share) $ (0.07) $ (0.11)  
Weighted average shares used in computing basic loss per share (in shares) 153,584 77,087  
Series A Preferred Stock [Member]
     
Other income (expense):      
Modification of preferred stock warrants 0 0 (2,306)
Preferred stock dividends 0 0 (334)
Series A 1 Preferred Stock [Member]
     
Other income (expense):      
Modification of preferred stock warrants 0 0 (16,393)
Preferred stock dividends $ 0 $ 0 $ (917)